RxDoctor Payments Data

Neil Padgett, MD

Internal Medicine · Glen Burnie, MDNPI 1831181833

Payments from drug & device makers

$13,308in general payments, 2019–2025

Across 761 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$904
  • Pfizer$831
  • Boehringer Ingelheim$823
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$13,289100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk119$2,068
AbbVie(2 entities)74$1,166
AstraZeneca58$1,083
Lilly USA, LLC60$904
Pfizer52$831
Boehringer Ingelheim43$823
Amgen(2 entities)34$615
Merck27$476
GSK21$409
Johnson & Johnson21$405
Daiichi Sankyo Inc.19$340
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC17$284
Abbott14$280
Viiv Healthcare Company12$261
Takeda Pharmaceuticals U.S.A., Inc.17$222
Exact Sciences10$214
Optinose US, Inc.12$210
Biohaven Pharmaceutical Holding Company Ltd.12$199
Lundbeck LLC9$191
Bayer8$167
Sanofi-aventis U.S. LLC12$162
Amarin Pharma, Inc.9$155
Astellas Pharma US Inc7$148
Gilead7$134
Eisai Inc.7$111
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$97
Idorsia Pharmaceuticals US Inc5$90
Biogen3$85
Dexcom, Inc.4$82
Corcept Therapeutics4$69
Biohaven Pharmaceuticals, Inc.4$60
Vertos Medical, Inc.1$59
Dynavax Technologies Corporation3$58
Jazz Pharmaceuticals Inc.3$54
Teva Pharmaceuticals USA, Inc.3$48
Axsome Therapeutics, Inc.2$45
Xeris Pharmaceuticals, Inc.3$45
Kowa Pharmaceuticals America, Inc.2$43
Medtronic3$42
Redhill Biopharma Inc.2$41
Mannkind Corporation3$36
Novartis2$33
Tris Pharma Inc2$33
Currax Pharmaceuticals LLC2$27
Ironwood Pharmaceuticals, Inc2$26
Genentech USA, Inc.2$26
Radius Health, Inc.1$24
Hikma Pharmaceuticals USA1$23
Sumitomo Pharma America, Inc.1$23
Globus Medical1$23
Neos Therapeutics, LP1$22
Ultragenyx Pharmaceutical Inc.1$21
Otsuka America Pharmaceutical, Inc.1$20
Kyowa Kirin, Inc.1$19
TMS Neurohealth Centers Inc.1$18
Azurity Pharmaceuticals, Inc.1$18
Endo Pharmaceuticals Inc.1$16
Organon1$16
Nabriva Therapeutics, PLC1$15
Paratek Pharmaceuticals, Inc.1$15

How this compares

$13,308 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$215,856
Medicare patients
426
Services billed
6,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide40$69,471
OzempicSemaglutide25$44,472
JardianceEmpagliflozin18$26,931
EliquisApixaban22$22,578
XareltoRivaroxaban12$15,497
FarxigaDapagliflozin Propanediol13$11,267
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,294
Novolog FlexpenInsulin Aspart14$3,264
Atorvastatin Calcium97$978
Tamsulosin Hcl40$916
Rosuvastatin Calcium24$691
Levothyroxine Sodium30$562
Metoprolol Succinate24$420
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide19$419
Montelukast Sodium36$419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$2,068$113,94465 claims
Boehringer IngelheimJardiance$823$26,93118 claims
PfizerEliquis$831$22,57822 claims
Johnson & JohnsonXarelto$405$15,49712 claims
AstraZenecaFarxiga$1,083$11,26713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →